NDLI: Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

Content Provider	Springer Nature : BioMed Central
Author	Chakaya, Jeremiah Mecha, Jared Beekman, Maarten
Abstract	Background Despite a high asthma burden in Kenya, insights into asthma management practices, including prescription of short-acting β2-agonists (SABAs), are lacking. Therefore, this study describes patient demographics, disease characteristics, and asthma treatment patterns in the Kenyan cohort of the SABA use IN Asthma (SABINA) III study. Methods Patients with asthma (aged ≥ 12 years) with medical records containing data for ≥ 12 months prior to the study visit from 19 sites across Kenya were included in this cross-sectional study and classified by investigator-defined asthma severity (guided by the 2017 Global Initiative for Asthma [GINA] recommendations) and practice type (primary/specialist care). Data on severe exacerbation history, prescribed asthma treatments, and over-the-counter (OTC) SABA purchases in the 12 months before the study visit and asthma symptom control at the time of the study visit were collated using electronic case report forms. All analyses were descriptive in nature. Results Overall, 405 patients were analyzed (mean age, 44.4 years; female, 68.9%), of whom 54.8% and 45.2% were enrolled by primary care clinicians and specialists, respectively. Most patients were classified with mild asthma (76.0%, GINA treatment steps 1−2) and were overweight or obese (57.0%). Only 19.5% of patients reported full healthcare reimbursement, with 59% receiving no healthcare reimbursement. The mean asthma duration of patients was 13.5 years. Asthma was partly controlled/uncontrolled in 78.0% of patients, with 61.5% experiencing ≥ 1 severe exacerbation in the preceding 12 months. Crucially, 71.9% of patients were prescribed ≥ 3 SABA canisters, defined as over-prescription; 34.8% were prescribed ≥ 10 SABA canisters. Additionally, 38.8% of patients purchased SABA OTC, of whom 66.2% purchased ≥ 3 SABA canisters. Among patients with both SABA purchases and prescriptions, 95.5% and 57.1% had prescriptions for ≥ 3 and ≥ 10 SABA canisters, respectively. Inhaled corticosteroids (ICS), ICS with a long-acting β2-agonist fixed-dose combination, and oral corticosteroid bursts were prescribed to 58.8%, 24.7%, and 22.7% of patients, respectively. Conclusions SABA over-prescription occurred in almost three-quarters of patients, with over one-third of patients purchasing SABA OTC. Therefore, SABA over-prescription is a major public health concern in Kenya, underscoring an urgent need to align clinical practices with latest evidence-based recommendations.
Related Links	https://bmcprimcare.biomedcentral.com/counter/pdf/10.1186/s12875-023-02030-8.pdf
Ending Page	13
Page Count	13
Starting Page	1
File Format	HTM / HTML
ISSN	27314553
DOI	10.1186/s12875-023-02030-8
Journal	BMC Primary Care
Issue Number	1
Volume Number	24
Language	English
Publisher	BioMed Central
Publisher Date	2023-07-08
Access Restriction	Open
Subject Keyword	General Practice Family Medicine Primary Care Medicine Asthma management Over-the-counter Prescription SABA Short-acting β2-agonist
Content Type	Text
Resource Type	Article
Subject	Family Practice
Journal Impact Factor	3.2/2023
5-Year Journal Impact Factor	3.3/2023

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Over-prescription of short-acting β₂-agonists for asthma in South Africa: Results from the SABINA III study.

Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III

SABA Overuse in Russia – Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study

SABA Overuse in Russia - Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study.

Over-prescription of short-acting β2-agonists for asthma in South Africa: Results from the SABINA III study

A Cross-Sectional Study on Prescription Patterns of Short-Acting β2-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort

A Cross-Sectional Study on Prescription Patterns of Short-Acting β₂-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort.

SABINA: An Overview of Short-Acting β₂-Agonist Use in Asthma in European Countries.

The Burden of Short-Acting β₂-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.

Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

Similar Documents

Over-prescription of short-acting β2-agonists for asthma in South Africa: Results from the SABINA III study.

Short-acting β2-agonist prescription patterns in patients with asthma in Turkey: results from SABINA III

SABA Overuse in Russia – Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study

SABA Overuse in Russia - Burden and Possible Causes: An Analysis of the Russian Population in the SABINA III (SABA use IN Asthma) Study.

Over-prescription of short-acting β2-agonists for asthma in South Africa: Results from the SABINA III study

A Cross-Sectional Study on Prescription Patterns of Short-Acting β2-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort

A Cross-Sectional Study on Prescription Patterns of Short-Acting β2-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort.

SABINA: An Overview of Short-Acting β2-Agonist Use in Asthma in European Countries.

The Burden of Short-Acting β2-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.

Over-prescription of short-acting β2-agonists remains a serious health concern in Kenya: results from the SABINA III study

Over-prescription of short-acting β₂-agonists for asthma in South Africa: Results from the SABINA III study.

A Cross-Sectional Study on Prescription Patterns of Short-Acting β₂-Agonists in Patients with Asthma: Results from the SABINA III Colombia Cohort.

SABINA: An Overview of Short-Acting β₂-Agonist Use in Asthma in European Countries.

The Burden of Short-Acting β₂-Agonist Use in Asthma: Is There an Italian Case? An Update from SABINA Program.